[Skip to Navigation]
Comment & Response
November 2017

Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply

Author Affiliations
  • 1Psychiatric Centre Copenhagen, University Hospital Copenhagen and Laboratory of Neuropsychiatry, University of Copenhagen, Copenhagen, Denmark
  • 2Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • 3Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York
  • 4Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York
  • 5Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York
  • 6Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York
  • 7Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
  • 8Steno Diabetes Center Copenhagen, University of Copenhagen, Copenhagen, Denmark
JAMA Psychiatry. 2017;74(11):1173-1174. doi:10.1001/jamapsychiatry.2017.2702

In Reply We thank Deutch for his thoughtful response to our study,1 in which we reported that the glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, reduces body weight, improves glucose tolerance, and decreases systolic blood pressure in patients with schizophrenia receiving clozapine or olanzapine. Deutch correctly pointed out that GLP-1 receptor stimulation can dampen activation of the reward pathways (eg, reduction of cocaine-induced dopamine elevation2) and therefore suggested that a detailed assessment of liraglutide-induced psychiatric symptoms, particularly the so-called negative symptoms, such as anhedonia and blunted affect, should be performed before GLP-1 receptor agonists are used to counter antipsychotic-induced body weight gain and metabolic disturbances.

Add or change institution